Oramed Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oramed Pharmaceuticals (ORMP).

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	—
May 20, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	—

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oramed Pharmaceuticals (NASDAQ:ORMP) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oramed Pharmaceuticals (NASDAQ:ORMP) with a Neutral.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Canaccord Genuity analyst Edward Nash maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Hold and lowers the price target from $3 to $2.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023

Benzinga Insights

PRO
HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) from Buy to Neutral.

Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold

Canaccord Genuity analyst Edward Nash downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) from Buy to Hold.

Benzinga Newsdesk

Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PRO
Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023

PRO
HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

PRO
Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold

People Also Watch

People Also Watch

Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PROHC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PROCanaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023

PROHC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

PROCanaccord Genuity Downgrades Oramed Pharmaceuticals to Hold

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PRO
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals

PRO
Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

PRO
HC Wainwright & Co. Downgrades Oramed Pharmaceuticals to Neutral

PRO
Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold